Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1995-06-12
1999-09-14
Guzo, David
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 255, C07H 2104
Patent
active
059524901
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the design and synthesis of oligonucleotides which can be used to inhibit the activity of viruses in vivo or in vitro and to treat viral-associated disease. These compounds can be used either prophylactically or therapeutically for diseases associated with viruses such as HIV, HSV, HCMV and influenza. Oligonucleotides capable of inhibiting phospholipase A.sub.2 enzyme activity are also provided which may be useful for the treatment of inflammatory disorders, as well as neurological conditions.
Oligonucleotides designed for the treatment of cancer and to retard aging are also contemplated by this invention.
BACKGROUND OF THE INVENTION
There have been many approaches for inhibiting the activity of viruses such as the human immunodeficiency virus (HIV), herpes simplex virus (HSV), human cytomegalovirus (HCMV) and influenza. Such prior art methods include nucleoside analogs (e.g., HSV) and antisense oligonucleotide therapies (e.g., HIV, influenza).
Prior attempts to inhibit HIV by various approaches have been made by a number of researchers. For example, Zamecnik and coworkers have used phosphodiester anti-sense oligonucleotides targeted to the reverse transcriptase primer site and to splice donor/acceptor sites, P. C. Zamecnik, J. Goodchild, Y. Taguchi, P. S. Sarin, Proc. Natl. Acad. Sci. USA 1986, 83, 4143. Goodchild and coworkers have made phosphodiester antisense compounds targeted to the initiation sites for translation, the cap site, the polyadenylation signal, the 5' repeat region, primer binding site, splice sites and a site between the gag and pol genes. J. Goodchild, S. Agrawal, M. P. Civeira, P. S. Sarin, D. Sun, P. C. Zamecnik, Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5507; U.S. Pat. No. 4,806,463. Agrawal and coworkers have used chemically modified antisense oligonucleotide analogs targeted to the cap and splice donor/acceptor sites. S. Agrawal, J. Goodchild, M. P. Civeira, A. H. Thornton, P. S. Sarin, P. C. Zamecnik, Proc. Nat'l. Acad. Sci. USA 1988, 85, 7079. Agrawal and coworkers have used antisense oligonucleotide analogs targeted to the splice donor/acceptor site inhibit HIV infection in early infected and chronically infected cells. S. Agrawal, T. Ikeuchi, D. Sun, P. S. Sarin, A. Konopka, J. Maizel, Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 7790.
Sarin and coworkers have also used chemically modified antisense oligonucleotide analogs targeted to the HIV cap and splice donor/acceptor sites. P. S. Sarin, S. Agrawal, M. P. Civeira, J. Goodchild, T. Ikeuchi, P. C. Zamecnik, Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7448. Zaia and coworkers have also used an antisense oligonucleotide analog targeted to a splice acceptor site to inhibit HIV. J. A. Zaia, J. J. Rossi, G. J. Murakawa, P. A. Spallone, D. A. Stephens, B. E. Kaplan, J. Virol. 1988, 62, 3914. Matsukura and coworkers have synthesized antisense oligonucleotide analogs targeted to the initiation of translation of the HIV rev gene mRNA. M. Matsukura, K. Shinozuka, G. Zon, Proc. Natl. Acad. Sci. USA 1987, 84, 7706; R. L. Letsinger, G. R. Zhang, D. K. Sun, T. Ikeuchi, P. S. Sarin, Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6553. Mori and coworkers have used a different antisense oligonucleotide analog targeted to the same region as Matsukura. K. Mori, C. Boiziau, C. Cazenave, Nucleic Acids Res. 1989, 17, 8207. Shibahara and coworkers have used antisense oligonucleotide analogs targeted to a splice acceptor site as well as the reverse transcriptase primer binding site.
S. Shibahara, S. Mukai, H. Morisawa, H. Nakashima, S. Kobayashi, N. Yamamoto, Nucl. Acids Res. 1989, 17, 239. Letsinger and coworkers have synthesized and tested a oligonucleotide analogs with conjugated cholesterol targeted to a splice site. K. Mori, C. Boiziau, C. Cazenave, Nucleic Acids Res. 1989, 17, 8207. Stevenson and Iversen have conjugated polylysine to antisense oligonucleotide analogs targeted to the splice donor and the 5'-end of the first exon of the HIV tat gene. M. Stevenson, P. L. Iversen, J. Gen. Virol. 1989, 70, 2673.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5514577 (1996-05-01), Draper et al.
Giovannangeli, et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 8631-8635.
McShan, et al., J. Biol. Chem., 1992, 267, 5712-5721.
Zahler, et al., Nature, 1991, 350, 718-720.
Agrawal, S., et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus", PNAS USA 1988, 85, 7079-7083.
Agrawal, et al., "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense oligodeoxynucleotides and their Phosphorothioate Analogues", PNAS USA 1989, 86, 7790-7794.
Bartlett, G., "Phosphorus assay in column chromatography", J. Biol. Chem., 1959, 234(3), 466-468.
Bomalaski, J. et al., "Human extracellular recombinant phospholipase A.sub.2 induces an inflammatory response in rabbit joints", J. of Immunology 1991, 146, 3904-3910.
Buck, H. et al., "Phosphate-methylayed DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity", Science 1990, 248, 208-212.
Counter, C. et al., "Telomere Shortening Associated with Chromosome Instability is Arrested in Immortal Cells Which Express Telomerase Activity", The EMBO J. 1992, 11(5), 1921-1929.
Crowl et al., "Induction of Phospholipase A.sub.2 Gene Expression in Human Hepatoma Cells by Mediators of the Acute Phase Response", J. Biol. Chem. 1991, 266, 2647-2651.
Davidson et al., "Inhibition of Phospholipase A.sub.2 by Lipocortins and Calpactins", J. Biol. Chem. 1987, 262, 1698-1705.
Farr et al., "Functional Reintroduction of Human Telomeres into Mammalian Cells", PNAS USA 1992, 88, 7006-7010.
Gattaz, et al., "Increased Serum Phospholipase A.sub.2 Activity in Schizophrenia: A Replication Study", Biol. Psychiatry 1990, 28, 495-501.
Gilman, S.C. and Chang, J., "Characterization of Interleukin 1 Induced Rabbit Chondrocyte Phospholipase A.sub.2 ", J. Rheumatol. 1990, 17, 1392-1396.
Gilman, et al., "Interleukin-1 Activates Phospholipase A.sub.2 in Human Synovial Cells, Arthritis and Rheumatism", Arthritis and Rheumatism 1988, 31, 126-130.
Goodchild, et al., "Inhibition of Human Immunodeficiency Virus Replication By Antisense Oligodeoxynucleotides", PNAS USA 1988, 85, 5507-5511.
Greider, C., "Telomeres", Current Opinion in Cell Biology 1991, 3, 444-451.
Harley, C. et al., "Telomeres Shorten During Ageing of Human Fibroblasts", Nature 1990, 345, 458-460.
Harley, C.B., Meth. Molec. Biol. 1990, 5, 25-32.
Hastie, N.D. et al., "Telomere Reduction in Human Colorectal Carcinoma and with Ageing", Nature 1990, 346, 866-868.
Hulkower, K.I. et al., "Interleukin -1.beta. stimulates cytosolic phospholipase A.sub.2 in rheumatoid synovial fibroblasts", Biochemical and Biophysical Research Communications 1992, 184(2), 712-718.
Kabanov et al., "A New Class of Antivirals: Antisense Oligonucleotides Combined with a Hydrophobic Substituent Effectively Inhibit Influenza Virus Reproduction and Synthesis of Virus-Specific Proteins in MDCK Cells", FEBS Letters 1990, 259, 327-330.
Kramer, I.M. et al., "1-0-Hexadecyl-2-O-methylglycerol, a novel inhibitor of protein kinase C, inhibits the respiratory burst in human neutrophils", J. of Biological Chemistry 1989, 264(10), 5876-5884.
Leiter et al., "Inhibition of influenza virus replication by phosphorothioate oligodexoynucleotides", PNAS USA 1990, 87, 3430-3434.
Letsinger et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", PNAS USA 1989, 86, 6553-6556.
Matsukura, M. et al., "Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus", Proc.Natl.Acad.Sci. USA 1987, 84, 7706-7710.
Mori, K. et al., "Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties, and anti-HIV activity", Nucleic Acids Research 1989, 17, 8207-8219.
Nakano, T. et al., "Group II Phospholipase A.sub.2 mR
Anderson Kevin P.
Bennett C. Frank
Brown-Driver Vickie L.
Chiang Ming-Yi
Ecker David J.
Guzo David
ISIS Pharmaceuticals Inc.
LandOfFree
Oligonucleotides having a conserved G4 core sequence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides having a conserved G4 core sequence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides having a conserved G4 core sequence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1511012